SpringerLink
Log in

Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Data availability

Anonymized data available upon reasonable request.

References

  1. Conway SE, Pua DKA, Holroyd KB, Galetta K, Bhattacharyya S (2022) Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors. Mult Scler. https://doi.org/10.1177/13524585221117949

    Article  PubMed  Google Scholar 

  2. Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1–8

    Article  CAS  PubMed  Google Scholar 

  3. Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol 21:1336–1342

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, Tietze JK, Ertl-Wagner B, Straube A, Kümpfel T, Dornmair K, Hohlfeld R (2016) CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol 80:294–300

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gettings EJ, Hackett CT, Scott TF (2015) Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 21:670

    Article  PubMed  Google Scholar 

  6. Gómez Vicente L, Rubio Viqueira B, Jimenez de las Peñas M, Garcia Cobos R, Pardo Moreno J, Arroyo Gonzalez R (2016) P04.07 relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab. Neuro Oncol 18:iv25

    Article  PubMed Central  Google Scholar 

  7. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP (1997) Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 73:57–62

    Article  PubMed  Google Scholar 

  8. Kroner A, Schwab N, Ip CW, Ortler S, Göbel K, Nave KA, Mäurer M, Martini R, Wiendl H (2009) Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am J Pathol 174:2290–2299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kyi C, Carvajal RD, Wolchok JD, Postow MA (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2:35

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT (2020) Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol 88:407–417

    Article  CAS  PubMed  Google Scholar 

  11. Lu BY, Isitan C, Mahajan A, Chiang V, Huttner A, Mitzner JR, Wesley SF, Goldberg SB (2021) Intracranial complications from immune checkpoint therapy in a patient with NSCLC and multiple sclerosis: case report. JTO Clin Res Rep 2:100183

    PubMed  PubMed Central  Google Scholar 

  12. Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D (2022) Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol 93:604–614

    Article  PubMed  Google Scholar 

  13. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D (2009) Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72:800–805

    Article  CAS  PubMed  Google Scholar 

  14. Oliveira MCB, de Brito MH, Simabukuro MM (2020) Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature. Front Neurol 11:538695

    Article  PubMed  PubMed Central  Google Scholar 

  15. Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M (2019) Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol 266:3163–3166

    Article  PubMed  Google Scholar 

  16. Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, Lopez-Chiriboga AS, Klein CJ, Mauermann M, Pittock SJ, Flanagan EP, Zekeridou A (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:e2442–e2452

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was received for conducting this study.

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA

    Shemonti Hasan, Onilia Zorio & Cristina Valencia-Sanchez

  2. Department of Neurology, Mayo Clinic, Rochester, MN, USA

    B. Mark Keegan, Brian G. Weinshenker, Eoin P. Flanagan, W. Oliver Tobin, Orhun H. Kantarci, Michel Toledano, Sean J. Pittock & Anastasia Zekeridou

  3. Department of Neurology, University of Virginia, Charlottesville, VA, USA

    Brian G. Weinshenker

  4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Eoin P. Flanagan, Sean J. Pittock & Anastasia Zekeridou

  5. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA

    Sebastian Lopez-Chiriboga

Authors
  1. Shemonti Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Onilia Zorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Mark Keegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian G. Weinshenker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eoin P. Flanagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Oliver Tobin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Orhun H. Kantarci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michel Toledano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sean J. Pittock
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sebastian Lopez-Chiriboga
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Anastasia Zekeridou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Cristina Valencia-Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: CV-S, AZ; methodology: SH, CV-S; acquisition, analysis, and interpretation of data: all authors; writing—original draft preparation: SH, OZ, CV-S; writing—review and editing: all authors; supervision: CV-S, AZ.

Corresponding author

Correspondence to Cristina Valencia-Sanchez.

Ethics declarations

Conflicts of interest

S. Hasan, O. Zorio, O.H. Kantarci, M. Toledano, and C. Valencia-Sanchez declare that they have no conflict of interest. B.M. Keegan is funded by the Applebaum Family and is a member of the Center for Multiple Sclerosis and Autoimmune Research Mayo Clinic, receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases, and is an Editorial Board member of Multiple Sclerosis and Related Disorders. B.G. Weinshenker reports consulting fees from CANbridge Pharmaceuticals, Horizon Pharmaceuticals, Roche/Genentech, and speaking fees from Mitsubishi Tanabe and Horizon Pharmaceuticals. He reports payment from MedImmune/VielaBio/Horizon for participation in the NMOSD adjudication committee for the inebilizumab clinical trial and from Alexion for participation in the NMOSD adjudication committee for the eculizumab clinical trial. He reports payment from UCB Biosciences for participation in the MOG-IgG associated disorders clinical trial adjudication committee. He received travel support from Mitsubishi Tanabe. He has a patent NMO-IgG for diagnosis of neuromyelitis optica with royalties received from RSR Ltd, Oxford University, and Hospices Civils de Lyon. E.P. Flanagan has served on advisory boards for Alexion, Genentech, UCB, and Horizon Therapeutics outside the submitted work; has a patent for DACH1-IgG as a biomarker of paraneoplastic autoimmunity pending; has received speaker honoraria from Pharmacy Times; has received royalties from UpToDate; was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics; has received funding from the National Institutes of Health (Grant R01NS113828); is a member of the medical advisory board of the MOG project; and is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. W.O. Tobin has received research funding from Mallinckrodt Inc, the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and the National Institutes of Health (Grant R01NS113803 and R01NS121928) outside the submitted work. He has received honoraria from Neurology Live and has co-edited Mayo Clinic Cases in Neuroimmunology. S.J. Pittock reported grants, personal fees, and nonfinancial support from Alexion and MedImmune/Viela Bio/Horizon (all compensation is paid directly to the Mayo Clinic); grants from the National Institutes of Health, Grifols, NovelMed, and F. Hoffmann-LaRoche/Roche/Genentech (all compensation is paid directly to Mayo Clinic); consulting for Astellas (compensation to Mayo Clinic and personal compensation); personal fees from Sage Therapeutics, UCB, and F. Hoffmann-LaRoche/Roche/Genentech; and had patent #8,889,102 issued, patent #9,891,219B2 issued, and a patent for GFAP-IgG; Septin-5-IgG; MAP1B-IgG; Kelch-like protein 11; PDE10A pending. A.S. Lopez-Chiriboga has served on advisory boards for Genentech and Horizon Therapeutics. A. Zekeridou reported grants from Roche/Genentech outside the submitted work and has a patent for DACH1-IgG as biomarker of neurological autoimmunity pending and a patent for PDE10A-IgG as biomarker of neurological autoimmunity pending.

Ethics approval

This research study was conducted retrospectively from data obtained for clinical purposes. This study was approved by the Mayo Clinic Institutional Review Board. All patients signed a consent to use their medical records for research.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hasan, S., Zorio, O., Keegan, B.M. et al. Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy. J Neurol 270, 4707–4712 (2023). https://doi.org/10.1007/s00415-023-11933-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-11933-6

Search

Navigation